Mosaic Biosciences Secures Financing from Telegraph Hill Partners to Support Commercial Growth and Expand Drug Discovery Capabilities and Services
Ingenia Therapeutics and Mosaic Biosciences Present Preclinical Data on the Variants of the Bispecific Antibody IGT-427 for the Treatment of Degenerative Retinal Diseases
Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration
Catalyst Biosciences Announces Global License and Collaboration Agreement to Develop Pegylated CB2892 for the Treatment of Dry Age-Related Macular Degeneration
Catalyst Biosciences and Mosaic Biosciences Present Preclinical Data on Pegylated CB2782 for the Treatment of Dry Age-Related Macular Degeneration
Catalyst Biosciences and Mosaic Biosciences Enter into Strategic Collaboration to Develop Intravitreal Anti-Complement Factor 3 (C3) Products for the Treatment of Dry AMD and Other Retinal Diseases